Anti-Mouse VEGFR-2 Monoclonal Antibodies for Flow Cytometry

PA007531.r1: Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa

Recombinant Rat IgG1 Monoclonal Antibody.
Clone: DC101.
Isotype: Rat IgG1 Kappa.
Source: The anti-mouse VEGFR-2 monoclonal antibody (clone: DC101) was produced in mammalian cells.
Conjugation: non-conjugated.
Specificity/Sensitivity: The recombinant VEGFR-2 monoclonal antibody (clone: DC101) specifically binds to the mouse VEGFR-2.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

PA007531.h1Fs: Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Human IgG1 Fc Silent Kappa

Recombinant Human IgG1 Monoclonal Antibody.
Clone: DC101.
Isotype: Human IgG1 Fc Silent Kappa.
Source: The anti-mouse VEGFR-2 monoclonal antibody (clone: DC101) was produced in mammalian cells.
Conjugation: non-conjugated.
Specificity/Sensitivity: The recombinant VEGFR-2 monoclonal antibody (clone: DC101) specifically binds to the mouse VEGFR-2.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

PA007777.h1Fs-b: Biotinylated Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Human IgG1 Fc Silent Kappa

Recombinant human IgG1 Monoclonal Antibody with site-directed biotinylation through the Avi tag at the C-terminus of the antibody heavy chain.
Clone: DC101.
Isotype: Human IgG1 Fc Silent Kappa.
Source: The site-directed biotinylated anti-mouse VEGFR-2 monoclonal antibody (clone: DC101) was produced in mammalian cells.
Conjugation: Biotin-conjugated.
Specificity/Sensitivity: The site-directed biotinylated recombinant DC101 antibody specifically binds to mouse VEGFR-2.
Applications: Flow cytometry (FC) with various dye conjugation through streptavidin; conjugation to streptavidin agarose beads or streptavidin magnetic beads.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The recombinant anti-mouse VEGFR-2 antibodies (clone of DC101) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of anti-mouse VEGFR-2 antibody for Flow Cytometry (Clone: DC101):

Cy5.5-Chitosan-anti-vascular endothelial growth factor receptor 2 monoclonal antibody DC101
Leung K.. Molecular Imaging and Contrast Agent Database (MICAD). 2004–2013. PMID: 22191115.
Vascular endothelial growth factor (VEGF) consists of at least six isoforms with various numbers of amino acids (121, 145, 165, 183, 189, and 206 amino acids) produced through alternative splicing (1). VEGF121, VEGF165, and VEGF189 are the forms secreted by most cell types and are active as homodimers linked by disulfide bonds. VEGF121 does not bind to heparin like the other VEGF species (2). VEGF is a potent angiogenic factor that induces proliferation, sprouting, migration, and tube formation of endothelial cells. There are three high-affinity tyrosine kinase VEGF receptors (VEGFRs) on endothelial cells (VEGFR-1, Flt-1; VEGFR-2, KDR/Flt-1; and VEGFR-3, Flt-4). Several types of non-endothelial cells such as hematopoietic stem cells, melanoma cells, monocytes, osteoblasts, and pancreatic β cells also express VEGFRs (1).
VEGFRs have been found to be overexpressed in various tumor cells and tumor-associated endothelial cells (3). Inhibition of VEGFR function has been shown to inhibit pathological angiogenesis as well as tumor growth and metastasis (4, 5). Radiolabeled VEGF has been developed as a tracer for imaging solid tumors and angiogenesis in humans (6-8). Chitosan (5 kDa) is a linear polysaccharide composed of D-glucosamine and N-acetylglucosamine subunits with numerous amine groups of D-glucosamine for ligand conjugation. A rat anti-VEGFR-2 monoclonal antibody (mAb), DC101, has been shown to inhibit angiogenesis with suppression of tumor growth and metastasis. Lee et al. (9) conjugated chitosan to DC101 mAb for labeling with Cy5.5 to form Cy5.5-chitosan-DC101 for NIR fluorescence imaging of VEGFR-2 expression under ischemic conditions.
Tags: activity of DC101 antibody; function of DC101 antibody

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Park JA, et al. J Immunother Cancer. 2023 Mar;11(3):e006680. doi: 10.1136/jitc-2023-006680. PMID: 36990507
Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGFR2 antibody (DC101) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used.
Tags: DC101 antibody; DC101 antibody for animal model

Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101
Kiessling F, et al. Neoplasia. 2004 May-Jun;6(3):213-23. doi: 10.1593/neo.3394. PMID: 15153333
The purpose of our study was the investigation of early changes in tumor vascularization during antiangiogenic therapy with the vascular endothelial growth factor (VEGF) receptor 2 antibody (DC101) using dynamic contrast-enhanced magnetic resonance imaging (DCE MRI). Subcutaneous heterotransplants of human skin squamous cell carcinomas in nude mice were treated with DC101. Animals were examined before and repeatedly during 2 weeks of antiangiogenic treatment using Gd-DTPA-enhanced dynamic T1-weighted MRI. With a two-compartment model, dynamic data were parameterized in "amplitude" (increase of signal intensity relative to precontrast value) and k(ep) (exchange rate constant). Data obtained by MRI were validated by parallel examinations of histological sections immunostained for blood vessels (CD31). Already 2 days after the first DC101 application, a decrease of tumor vascularization was observed, which preceded a reduction of tumor volume. The difference between treated tumors and controls became prominent after 4 days, when amplitudes of treated tumors were decreased by 61% (P =.02). In line with change of microvessel density, the decrease in amplitudes was most pronounced in tumor centers. On day 7, the mean tumor volumes of treated (153 +/- 843 mm(3)) and control animals (596 +/- 384 mm(3)) were significantly different (P =.03). After 14 days, treated tumors showed further growth reduction (83 +/- 93 mm(3)), whereas untreated tumors (1208 +/- 822 mm(3)) continued to increase (P =.02). Our data underline the efficacy of DC101 as antiangiogenic treatment in human squamous cell carcinoma xenografts in nude mice and indicate DCE MRI as a valuable tool for early detection of treatment effects before changes in tumor volume become apparent.
Tags: DC101 antibody for flow cytometry; DC101 antibody for mouse tumor model

Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma
Suzuki H., et al. Hepatol Int. 2024 Apr;18(2):610-622. doi: 10.1007/s12072-023-10603-z. PMID: 37864726
We established immune syngeneic orthotopic HCC mouse models using Hep-55.1C and Hep-53.4, and treated them with MTAs (lenvatinib, sorafenib, regorafenib, cabozantinib, and DC101 as anti-vascular endothelial growth factor receptor-2 antibodies, and AZD4547 as a fibroblast growth factor receptor (FGFR)-1/2/3/4 inhibitor) for 2 weeks.
Tags: DC101 mAb for animal model; DC101 mAb for flow cytometry

Dextran-conjugated vascular endothelial growth factor receptor antibody for in vivo melanoma xenografted mouse imaging
Kim EM, et al. Cancer Biother Radiopharm. 2012 Mar;27(2):141-8. doi: 10.1089/cbr.2011.0977. PMID: 22149589
Intact immunoglobulin G antibody has a relatively large molecule size of approximately 150 kDa that remains in the bloodstream for many weeks, which is a considerable disadvantage when it is used to carry radioactive materials for imaging. To lower background activity and increase the contrast of images, we investigated antivascular endothelial growth factor (VEGF) receptor 2 antibody (DC101) conjugated dextran for VEGF receptor 2 imaging in tumor xenografted mice. DTPA-conjugated aminodextran was synthesized, reacted with sulfo-LC-SPDP, and then reacted with DC101. The binding affinity of DTPA-dextran-DC101 to Flk-1 was measured. The gamma imaging and biodistributions of (99m)Tc-DTPA-dextran-DC101, (99m)Tc-DTPA-DC101, and (125)I-DC101 were studied in B16F10 melanoma xenografted mice. The dissociation values for DC101, DTPA-DC101, and DTPA-dextran-DC101 were 22.48, 3.05, and 14.74 pM, respectively. In gamma images, (99m)Tc-DTPA-dextran-DC101 showed weak liver uptake and rapid kidney elimination. In biodistribution results, the liver uptake of (99m)Tc-DTPA-dextran-DC101 was similar with that of (99m)Tc-DTPA-DC101 at each time point. However, the blood activity of (99m)Tc-DTPA-dextran-DC101 has shown significant differences, compared with (99m)Tc-DTPA-DC101 at all time points. The tumor accumulation of dextran-conjugated antibody was increased with time, whereas that of dextran nonconjugated antibody decreased. In particular, the pattern of tumor uptake of (99m)Tc-DTPA-dextran-DC101 was similar to that of (125)I-DC101, so this was thought to reflect the kinetics of DC101, unlike the nonconjugated form. The results of this study suggested that introduction of dextran moiety to make (99m)Tc-radiolabeled DC101 imaging agent could provide better images with the impaired background and the steady increasing binding to the receptor. However, further studies are necessary to improve clinical pharmacokinetics, such as enhancement of tumor uptake and impaired renal uptake.
Tags: DC101 mAb; DC101 monoclonal antibody

For more references about anti-mouse VEGFR-2 antibody for Flow Cytometry (Clone: DC101), please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following anti-mouse PD1 (PD-L1) and VEGFR2 monoclonal antibodies:
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD 1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)
In vivo grade recombinant anti-mouse VEGFR2 monoclonal antibodies (Clone DC101)

Syd Labs provides the following anti-mouse PD-1 / VEGFR-2 bispecific antibodies:
In vivo grade recombinant anti-mouse PD 1 / VEGFR2 bispecific antibodies (Clone RMP1-14.1 / DC101)
In vivo grade recombinant anti-mouse PD-1 / VEGFR-2 bispecific antibodies (Clone 29F.1A12.1 / DC101)

Syd Labs provides the following anti-mouse PD-L1 / VEGFR-2 bispecific antibodies:
In vivo grade recombinant anti-mouse PDL1 / VEGFR-2 bispecific antibodies (Clone 10F.9G2.1 / DC101)